July 15th, 2010
Basic Cardiovascular Sciences 2010 Scientific Sessions – Technological and Conceptual Advances in Cardiovascular Disease
Larry Husten, PHD
NEJM — Recent Cardiology Articles- Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 October 1, 2026In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.
- Statins in Older Adults — Evidence at Last October 1, 2026For decades, one of the most important unresolved questions in preventive cardiovascular medicine has been whether statin therapy should be initiated for primary prevention in healthy older adults. Although age is among the strongest determinants of absolute risk, the benefits of statin therapy beyond 70 to 75 years of age...
- Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults October 1, 2026In older adults without cardiovascular disease, treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival.
- Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke September 24, 2026Stroke is a severe and common complication of atrial fibrillation. Anticoagulation with vitamin K antagonists or with direct oral anticoagulants (DOACs) prevents the majority of strokes in patients with atrial fibrillation and at least two clinical risk factors for stroke (Table 1).1 Patients who receive DOACs or vitamin...
- Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk September 24, 2026In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation.
- Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 October 1, 2026